Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SCOTTSDALE, Ariz. — A novel therapeutic approach ...
Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis. A new review of the latest therapies for myasthenia gravis (MG), including ...
Viridian Therapeutics Inc. has disclosed a preclinical portfolio of neonatal Fc receptor (FcRn) inhibitors designed for next-generation treatment of antibody-mediated autoimmune diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results